Fairfax Financial Holdings Limited

Fairfax reported operating income from insurance and reinsurance of $1.1 billion in Q2 2026, underwriting income of $459 million versus $427 million a year ago, interest and dividend income of $737 million versus $660 million, profits of associates of $43 million versus $131 million, and net investment gains of $769 million. Net earnings were $1.4 billion in the quarter and $2.1 billion for the first six months, while book value per share was $1,304 at quarter-end, up 4.8% from year-end 2025 adjusted for the $15 dividend. Gross premiums written were $9.4 billion, up 4.1% year over year, and the combined ratio was 93.1% versus 93.3% in Q2 2025. Management did not provide explicit next-quarter earnings guidance, but reiterated prior commentary that associate income plus consolidated investments has been running above the roughly $1 billion level previously discussed, and said interest and dividend income is running at about a 5% yield as the portfolio grows. They also pointed to continued premium growth in international operations and to discipline in a softening North American market.

Peter Clarke struck a confident but disciplined tone, describing the quarter as strong despite pricing pressure in insurance, especially in North American property lines. He said Fairfax is prioritizing bottom-line profitability over top-line growth, using diversification by product and geography to offset softening conditions. He also highlighted major capital moves and partnerships, including the Poseidon sale, Kennedy-Wilson privatization, Andrew Peller, and Sleep Country/Sleep Number, as evidence of active capital deployment and long-term optionality.

Amy Sherk focused on transaction accounting, capital position, and balance sheet strength. She detailed the $1.9 billion Poseidon sale and the $838 million realized gain, the Kennedy-Wilson/Kona BidCo structure, and upcoming deals including Andrew Peller for approximately $233 million, Sleep Number for approximately $530 million, Fairfax India’s IIFL Capital investment for approximately $417 million, and the Eurobank/Eurolife transaction for approximately $930 million. She said Fairfax held $2.3 billion of cash and investments at the holding company, had an undrawn $2 billion revolver, and had $4.4 billion of excess fair value over carrying value in noninsurance associates and market-traded consolidated subsidiaries.

Analysts focused on whether softening in property pricing is broadening into casualty, and Peter Clarke said the pressure is mainly still in property, though casualty softness may begin to appear. He said the company is responding by favoring higher-margin business and leaning on its international businesses, which are growing faster than North America. Questions also covered the partial sale of the Fairfax TRS, real-estate exposure through Kennedy-Wilson, the pace of associate income, float growth, leverage, and interest income; management said the TRS sale was not a signal that the stock is unattractive, float should be judged over a long horizon, debt has mostly replaced preferred shares on better terms, and interest/dividend income is mostly a function of a larger portfolio and higher reinvestment yields.